Study guide
6.4 Collaborative Drug Therapy Management (§6801-a) & Non-Patient-Specific Orders
New York MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the NY MPJE Exam 1.2 Study Strategy & Federal vs. New York Law Hierarchy
2 Federal Pharmacy Law: Controlled Substances
2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Registration, Forms & Security 2.3 Federal Food, Drug, and Cosmetic Act (FDCA)
3 Federal Pharmacy Law: Privacy & Supply Chain
3.1 HIPAA & Patient Privacy 3.2 OBRA '90, Medicare/Medicaid & DUR 3.3 DSCSA & Drug Supply Chain Integrity
4 Area 1a: NYSED, Board & Pharmacist Licensure
4.1 NYSED Office of the Professions, Board of Pharmacy & Education Law Article 137 4.2 Pharmacist Licensure: Education, NAPLEX/MPJE & Internship 4.3 License by Endorsement, Renewal & Continuing Education
5 Area 1b: Interns, Technicians & Discipline
5.1 Pharmacy Interns & Limited Permits 5.2 Registered Pharmacy Technicians (RPhT) & Supervision Ratios 5.3 Professional Misconduct, Discipline & Impaired Practitioner Programs
6 Area 2a: Prescribing, Controlled Substances & Collaborative Practice
6.1 Prescription Requirements & Practitioner Authority 6.2 Controlled Substance Prescribing & the NY EPCS Mandate 6.3 Refills & Authority Limitations 6.4 Collaborative Drug Therapy Management (§6801-a) & Non-Patient-Specific Orders
7 Area 2b: Counseling, Immunization & Public Health
7.1 Patient Counseling & Documentation 7.2 Pharmacist Immunization Authority 7.3 Naloxone Access & Public Health Programs 7.4 Patient Confidentiality & Pharmacy Records
8 Area 3a: Verification, Transfers & DUR/I-STOP
8.1 Legitimate Medical Purpose & Corresponding Responsibility 8.2 Prescription Transfers Between Pharmacies 8.3 Prospective DUR & the I-STOP PMP Registry 8.4 Refill Exceptions & Emergency Dispensing
9 Area 3b: Labeling, Packaging & Substitution
9.1 Labeling of Dispensed Drugs 9.2 Packaging: PPPA & Child-Resistant Containers 9.3 Generic Substitution & Interchangeable Biologics (§6816-a) 9.4 OTC, Behind-the-Counter & Restricted Nonprescription Sales
10 Area 4a: Records, Inventories & Delivery
10.1 Ordering, Acquisition & Distribution Records 10.2 Recordkeeping, Storage & Handling 10.3 Controlled Substance Inventories & BNE Registration 10.4 Delivery & Mail-Order Dispensing
11 Area 4b: Compounding, Central Fill & Facilities
11.1 Compounding: Non-Sterile, Sterile & Hazardous Drugs 11.2 Central Fill, Centralized Processing & Shared Pharmacy Services 11.3 Automated Dispensing & Telepharmacy 11.4 Pharmacy Establishment Registration, Inspections & Discipline
12 Test-Day Strategy & Final Review
12.1 When New York Law Is Stricter Than Federal Law 12.2 Test-Day Strategy & Common Traps
6.4 Collaborative Drug Therapy Management (§6801-a) & Non-Patient-Specific Orders
Key Takeaways Explain This Topic AI
Collaborative Drug Therapy Management under Education Law §6801-a is patient-specific and requires the collaborating physician to be employed by or affiliated with the same facility as the pharmacist; it does not authorize nurse practitioners as collaborating prescribers.
Pharmacists qualify for CDTM through a PharmD/MS-in-Clinical-Pharmacy path (2 years' experience, including 1 year of clinical facility consultation) or a BS-in-Pharmacy path (3 of the last 7 years' experience, including 1 year in a clinical facility setting), plus written patient consent before services begin.
Non-patient-specific orders under 8 NYCRR §63.9 (implementing Education Law §§6527, 6801, and 6909) are population-level, may be issued by either a physician or a certified nurse practitioner, and authorize pharmacists to administer immunizations or dispense self-administered hormonal contraceptives after Board-approved training.
If the DOH Commissioner determines there is an outbreak of disease or an imminent threat of one, the Commissioner may issue a non-patient-specific regimen applicable statewide under 8 NYCRR §63.9(a)(1)(b)(ii) — the model used for New York's statewide naloxone standing order under PHL §3309.
The MPJE tests the distinction sharply: CDTM is patient-specific, physician-only, and PharmD-qualification-driven, while non-patient-specific orders are population-level, physician-or-NP-issued, and activity-specific-training-driven.
Last updated: July 2026
Collaborative Drug Therapy Management — Education Law §6801-a
Collaborative Drug Therapy Management (CDTM) is defined by Education Law §6801-a as "the performance of clinical services by a pharmacist relating to the review, evaluation and management of drug therapy" for a patient being treated by a physician for a specific disease or associated disease states. CDTM operates under a written agreement or protocol with a voluntarily participating physician , consistent with the policies, procedures, and protocols of the facility where the care is delivered.
Two structural limits matter most for the exam. First, CDTM under §6801-a is patient-specific , not a population-level standing order — it is built around an individual patient's treatment relationship with a physician. Second, it is institutionally bounded : the participating physician must be employed by or affiliated with the same facility as the collaborating pharmacist. §6801-a does not extend collaborating-prescriber status to nurse practitioners, and it does not authorize a community pharmacist to enter a CDTM protocol with an unaffiliated outside physician.
Pharmacist eligibility to practice CDTM follows one of two paths:
A Doctor of Pharmacy (PharmD) or Master of Science in Clinical Pharmacy , current unrestricted New York licensure, and a minimum of 2 years' experience , including at least 1 year of clinical health-facility consultation with physicians regarding medication therapy; or
A Bachelor of Science in Pharmacy , with a minimum of 3 years' experience within the preceding 7 years , including at least 1 year in a clinical health-facility setting .
Permissible clinical actions under a CDTM protocol include adjusting or managing an existing drug regimen — strength, frequency, or route of administration — but not substituting a different drug unless the protocol expressly authorizes it; ordering disease-related laboratory tests when the protocol specifically authorizes it; and performing routine monitoring functions such as vital-sign assessment. Written patient consent is mandatory before CDTM services begin, and participation remains voluntary for the pharmacist, the physician, and the patient. §6801-a has historically operated as a demonstration program subject to periodic legislative reauthorization rather than a permanent grant of authority, so candidates should confirm current reauthorization status rather than assume it never expires.
A Different Authority: Non-Patient-Specific Orders — 8 NYCRR §63.9
The MPJE regularly tests whether candidates can distinguish §6801-a CDTM from a separate, broader authority: non-patient-specific orders , authorized under Education Law §§6527, 6801, and 6909 and implemented at 8 NYCRR §63.9 . Where CDTM is patient-specific and physician-only, non-patient-specific orders are population-level and may be issued by either a New York-licensed physician or a New York-certified nurse practitioner with a practice site in the state.
New York recognizes two pharmacist activities under non-patient-specific orders: administering immunizations , and dispensing self-administered hormonal contraceptives (FDA-approved oral contraceptives, contraceptive vaginal rings, and contraceptive patches used to prevent pregnancy), each requiring the pharmacist to complete Board-approved training first. A non-patient-specific order authorizes one or more certified pharmacists — named individually, or identified through employment or contract with an entity legally authorized to provide pharmacy services — to act on a defined group of individuals for a prescribed period , rather than for a single named patient. For immunizations specifically, adults 18 and older may receive the full range of ACIP-aligned vaccines under a non-patient-specific order, while patients ages 2 through 18 are limited to influenza vaccine only.
Statewide Orders During an Outbreak
8 NYCRR §63.9(a)(1)(b)(ii) gives the DOH Commissioner a further, escalated tool: if the Commissioner determines that there is an outbreak of disease, or an imminent threat of an outbreak of disease, the Commissioner may personally issue a non-patient-specific regimen applicable statewide — replacing the need for an individual physician or nurse practitioner order at every practice site. The working, real-world example of this authority in action is the naloxone standing order under PHL §3309 : the DOH Commissioner issues and periodically renews a statewide standing order (the most recent renewal runs from February 12, 2026 through February 12, 2028) that lets every pharmacist registered and in good standing with the New York Board of Pharmacy dispense the opioid antagonist naloxone to anyone who requests it — including people at risk of overdose and third parties positioned to assist them — without any patient-specific prescription at all.
The Distinction the Exam Wants You to Draw
Feature CDTM — §6801-a Non-Patient-Specific Order — Part 63
Patient specificity Patient-specific; built on an existing physician-patient relationship Population-level; covers a defined group, not one named patient
Who may issue/collaborate Physician employed by or affiliated with the same facility as the pharmacist Physician OR nurse practitioner licensed/certified in New York
Pharmacist qualification PharmD/MS + 2 yrs (1 yr clinical) or BS + 3 of last 7 yrs (1 yr clinical) Board-approved training in the specific activity (e.g., immunization certification)
Typical clinical scope Adjusting an existing drug regimen, ordering authorized labs, routine monitoring Administering immunizations; dispensing self-administered hormonal contraceptives
Statewide escalation Not applicable DOH Commissioner may issue a statewide order during a disease outbreak or imminent threat
Scenario
A community pharmacist without a PharmD and without documented clinical-facility experience wants to independently titrate a patient's antihypertensive regimen under a protocol signed by a physician who has no affiliation with the pharmacist's employer. This fails §6801-a on two grounds — pharmacist qualification and the same-facility physician requirement — regardless of how well-documented the protocol is. Contrast that with the same pharmacist administering an influenza vaccination to a 10-year-old under a non-patient-specific order signed by a certified nurse practitioner: that is lawful under Part 63, provided the pharmacist holds the required immunization certification.